CBD HPO, an evolution in cannabis derivatives
With the evolution of knowledge surrounding molecules derived from cannabis, new products regularly appear on the market, each time sparking questions and interest. One of these is HPO CBD (hexahydrocannabinol), a synthetic cannabinoid that shares similarities with THC and CBD, which are traditionally extracted from the cannabis plant.
What is CBD HPO?
CBD HPO is a hydrogenated derivative of tetrahydrocannabinol (THC) and belongs to the hexahydrocannabinol family. As mentioned above, it is a synthetic cannabinoid, meaning that it is not naturally present in the cannabis plant, unlike THC and CBD, but rather obtained through chemical processes.
The effects of CBD HPO
Unlike THC, which has psychotropic properties and can cause euphoric and addictive effects, CBD HPO is distinguished by milder and more moderate effects. In particular, it does not lead to euphoria or addiction. This characteristic could be appealing to those who wish to enjoy the potential benefits of cannabis without experiencing its undesirable side effects.
Current regulations on cannabis derivatives
The case of CBD
In recent years, CBD (cannabidiol) has received increasing attention from both consumers and health authorities. In France, this molecule is not considered a narcotic and is therefore authorized for sale under certain conditions, particularly regarding its origin and its THC concentration of less than 0.2%. However, regulations surrounding CBD remain somewhat ambiguous and can vary from one country to another within the European Union.
The situation of CBD HPO: between uncertainty and vigilance
Regarding CBD HPO, no specific legislation currently seems to govern its use and marketing. This means it can be sold freely, but also thatno official controls are in place to ensure its quality and safety. Many specialists are therefore raising concerns about the potential risks associated with this lack of regulation, both in terms of psychoactive effects and the repercussions on consumers' health. These concerns lead us to ask the question:
- Should HPO CBD be regulated, like CBD or other cannabis derivatives?
The issues and challenges surrounding CBD HPO
Beyond regulatory issues, CBD HPO also raises other problems and challenges that deserve special attention :
- Conducting scientific studies on the effects and safety of HPO CBD: While the potential benefits of cannabis have been known for a long time, those of synthetic cannabinoids like HPO CBD remain to be discovered.
- Establishing a suitable legal framework: The current maturity of this market requires adequate regulation to ensure consumer safety while allowing businesses to develop.
- Informing the general public: It is essential to counter misinformation and help consumers better understand the differences between the various products available.
In conclusion, while CBD HPO raises many questions, it also represents an opportunity to renew our approach to cannabis and its therapeutic applications. To achieve this, it is imperative to conduct adequate research and adopt appropriate legislation.
Sources
- https://www.la-croix.com/France/CBD-HHC-Ou-reglementation-derives-cannabis-2023-06-23-1201272787
- https://www.midilibre.fr/2023/05/11/hhc-tout-ce-quil-faut-savoir-sur-ce-cannabinoide-de-synthese-en-vente-libre-11189303.php
Editor-in-Chief specializing in CBD
Julien, born on July 17, 1978, in the Paris region, is a prominent writer and expert in the field of CBD products. Following his studies, Julien developed a passion for natural remedies, including CBD. In 2022, he joined the CBD.fr team as an expert and regular contributor. Thanks to his scientific expertise and clear writing style, Julien helps demystify the complexities of CBD, while highlighting its benefits and potential applications through his articles and conference presentations.
